US4096280A - Arylenedioxy-bis-diketones - Google Patents

Arylenedioxy-bis-diketones Download PDF

Info

Publication number
US4096280A
US4096280A US05/761,944 US76194477A US4096280A US 4096280 A US4096280 A US 4096280A US 76194477 A US76194477 A US 76194477A US 4096280 A US4096280 A US 4096280A
Authority
US
United States
Prior art keywords
bis
benzene
dipropionylheptyloxy
heptanedione
phenylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US05/761,944
Inventor
Guy Dominic Diana
Philip Michael Carabateas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STWB Inc
Original Assignee
Sterling Drug Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sterling Drug Inc filed Critical Sterling Drug Inc
Priority to US05/761,944 priority Critical patent/US4096280A/en
Priority to IE8/78A priority patent/IE46495B1/en
Priority to GB735/78A priority patent/GB1561672A/en
Priority to NZ186219A priority patent/NZ186219A/en
Priority to AU32468/78A priority patent/AU516354B2/en
Priority to FR7801263A priority patent/FR2377993A1/en
Priority to BE1008651A priority patent/BE863007A/en
Priority to SE7800621A priority patent/SE7800621L/en
Priority to CH53678A priority patent/CH629741A5/en
Priority to CA295,226A priority patent/CA1084065A/en
Priority to DK25178A priority patent/DK25178A/en
Priority to LU78914A priority patent/LU78914A1/en
Priority to DE19782802281 priority patent/DE2802281A1/en
Priority to JP476078A priority patent/JPS53101319A/en
Priority to NL7800668A priority patent/NL7800668A/en
Application granted granted Critical
Publication of US4096280A publication Critical patent/US4096280A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C07C45/71—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form being hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
    • C07C49/255—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing ether groups, groups, groups, or groups

Definitions

  • Toray Industries British Pat. No. 1,200,834 (Aug. 5, 1970) discloses acyclic substances useful as intermediates for preparing surface active agents, lubricants and cosmetic perfumes.
  • aliphatic diketones such as (CH 3 CO) 2 CHC(CH 3 ) ⁇ CHCH 2 CH 2 C(CH 3 ) ⁇ CHCH(COCH 3 ) 2 .
  • n and n are integers from 3 to 7, the sum of m and n ranging from 7 to 14.
  • the reaction is carried out stepwise, first with one molar equivalent, relative to the bisphenol, of Hal--(C m H 2m )--CH(COR) 2 to produce a hydroxyaryloxyalkyldiketone of the formula (ROC) 2 CH--(C m H 2m )--O--Ar--OH; and second with one molar equivalent or an excess of Hal--(C n H 2n )--CH(COR) 2 .
  • the halo group(s) can be any of the four halogens, fluorine, chlorine, bromine or iodine.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Phenylenedioxy-bis-dikeones having the formula ##STR1## useful as antiviral agents, are prepared by etherification of dihydric phenols and alkylation of beta-dikeones.

Description

BACKGROUND OF THE INVENTION
(a) Field of the Invention
This invention relates to novel arylenedioxy-bis-diketones, to the preparation thereof, and to compositions and methods of use thereof as antiviral agents.
(B) Description of the Prior Art
Toray Industries British Pat. No. 1,200,834 (Aug. 5, 1970) discloses acyclic substances useful as intermediates for preparing surface active agents, lubricants and cosmetic perfumes. Among the substances disclosed are aliphatic diketones such as (CH3 CO)2 CHC(CH3)═CHCH2 CH2 C(CH3)═CHCH(COCH3)2.
Collins and Diana U.S. Pat. No. 3,933,837 (Jan. 20, 1976) discloses aryloxyalkyldiketones having antiviral activity, including compounds of the structure
RO--Ar--O--(CH.sub.2).sub.n --CH(COC.sub.2 H.sub.5).sub.2
wherein Ar is phenylene or substituted phenylene, and R is hydrogen, alkyl or benzyl.
SUMMARY OF THE INVENTION
In a composition of matter aspect, the invention relates to compounds of the formula ##STR2## wherein: R is alkyl of 1-4 carbon atoms;
Ar is 1,3- or 1,4-phenylene in which the phenyl ring can be further substituted by one or two methyl, ethyl or halo groups;
m and n are integers from 3 to 7, the sum of m and n ranging from 7 to 14.
In a further composition of matter aspect, the invention relates to a composition for combatting viruses which comprises an antivirally effective amount of at least one compound of formula I in admixture with a suitable carrier or diluent.
In a process aspect, the invention relates to a process for preparing a compound of formula I which comprises:
(A) INTERACTING A COMPOUND OF THE FORMULA HO--Ar--OH successively with molar equivalent amounts of compounds of the formulas Hal--(Cm H2m)'CH(COR)2 and Hal--(Cn H2n)--CH(COR)2, where Hal is bromine or iodine, or, where m an n are identical integers, with at least two molar equivalents of Hal--(Cm H2m)--CH(COR)2, all in the presence of a base in an inert organic solvent; or
(B) INTERACTING A COMPOUND OF THE FORMULA Hal--(Cm H2m)--O--Ar--O--(Cn H2n)--Hal, where Hal is bromine or iodine, with an alkali metal salt or heavy metal chelate of a diketone, RCOCH2 COR, in an inert organic solvent.
In a further process aspect, the invention relates to a method of combatting viruses which comprises contacting the locus of said viruses with a composition containing an anti-virally effective amount of at least one compound of formula I in admixture with a suitable carrier or diluent.
DETAILED DESCRIPTION INCLUSIVE OF PREFERRED EMBODIMENTS
The compounds of formula I are prepared by either of two processes which however are closely related chemically since they both involve elimination of hydrogen halide in the presence of a base.
The first synthetic approach comprises the reaction of a difunctional phenol, HO--Ar--OH, with a haloalkyldiketone in the presence of a base. The base is preferably one which converts the phenol to its alkali metal salt and includes such bases as sodium hydroxide, lithium hydride, potassium hydroxide, potassium carbonate and the like. The reaction takes place in an inert organic solvent, slowly at ambient temperature (20° C.) and more rapidly at elevated temperatures, preferably between about 50° C. and 100° C. In the haloalkyldiketone the halogen atom is preferably bromine or iodine.
In the case where m is different from n in formula I, the reaction is carried out stepwise, first with one molar equivalent, relative to the bisphenol, of Hal--(Cm H2m)--CH(COR)2 to produce a hydroxyaryloxyalkyldiketone of the formula (ROC)2 CH--(Cm H2m)--O--Ar--OH; and second with one molar equivalent or an excess of Hal--(Cn H2n)--CH(COR)2.
In the case where m is the same as n in formula I, the reaction can be carried out in a single step, with two or more molar equivalents of Hal--(Cm H2m)--CH(COR)2.
The intermediate haloalkyldiketones are prepared by interacting an alkali metal enolate salt or heavy metal chelate of a diketone (RCO)2 CH2 with an alkylene dihalide, Hal--(Cm H2m)--Hal or Hal--(Cn H2n)--Hal. The reaction takes place in an inert solvent under anhydrous conditions at ambient temperature or slightly above (20°-70° C.) using equimolar quantities of reactants or a stoichiometric excess of dihalide.
The second synthetic approach comprises the reaction of a phenylene-bis(oxyalkyl halide), Hal--(Cm H2m)--O--Ar--O--(Cn H2n)--Hal, wherein Hal is preferably bromine or iodine, with an alkali metal salt or heavy metal chelate of a diketone, RCOCH2 COR, in an inert organic solvent. The reaction is analogous to that used for the preparation of the intermediate haloalkyldiketones in the first synthetic approach.
The intermediates, Hal--(Cm H2m)--O--Ar--O--(Cn H2n)--Hal, are prepared by a method analogous to the final step of the first synthetic approach, that is by stepwise reaction of a bisphenol with equimolar quantities of Hal--(Cm H2m)--Hal and Hal--(Cn H2n)--Hal; or with an excess of Hal--(Cm H2m)--Hal, if m is identical with n.
The compounds of formula I where m is identical with n are preferred because of the relative simplicity of their preparation. Compounds where Cm H2m and Cn H2n are straight chain alkylene are also ordinarily preferred, although branched chain compounds are clearly within the purview of the invention.
In compounds of formula I where the Ar nucleus is substituted by halo, the halo group(s) can be any of the four halogens, fluorine, chlorine, bromine or iodine.
The structures of the compounds of the invention were established by the modes of synthesis, by elementary analysis, and by infrared and nuclear magnetic resonance spectral determinations.
Biological evaluation of the compounds of the invention has shown that they possess antiviral activity in vitro and in vivo. The in vitro testing of the compounds against Herpes virus type 2 showed that they had minimal growth inhibitory concentrations (mic) ranging from about 1.5 to about 25 micrograms per milliliter. The mic values were determined by standard serial dilution procedures.
The antiviral compositions are formulated by preparing a dilute solution or suspension in an organic or aqueous-organic medium, for example ethyl alcohol, acetone, dimethyl sulfoxide, and the like; and are applied to the locus to be disinfected by conventional means such as spraying, swabbing or immersing. Alternatively, the compounds can be formulated as ointments or creams by incorporating them in conventional ointment or cream bases, such as alkylpolyether alcohols, cetyl alcohol, stearyl alcohol and the like; as jellies by incorporating them in conventional jelly bases such as glycerin and tragacanth; or as aerosol sprays or foams.
The following examples will further illustrate the invention.
EXAMPLE 1 (a) 4-(6-Bromohexyl)-3,5-heptanedione.
A solution of 64.1 g of 3,5-heptanedione in 200 ml. of dimethylformamide was added over a period of 1 hour to a suspension of 3.65 g. of lithium hydride in 400 ml. of dimethylformamide. The mixture was stirred for one hour and 488 g. of 1,6-dibromohexane was then added all at once. The reaction mixture was warmed at 60°-70° C. for 24 hours. The volatile solvent was removed and the residue partitioned between water and methylene dichloride. The methylene dichloride solution was concentrated and the residue distilled to give 65.0 g. of 4-(6-bromohexyl)-3,5-heptanedione, b.p. 118°-124° C. (0.005 mm.).
By replacing the 1,6-dibromohexane in the foregoing preparation by a molar equivalent amount of 2-ethyl-1,3-dibromopropane or 2,4-dimethyl-1,5-dibromopentane, it is contemplated that there can be obtained, respectively, 4-(3-bromo-2-ethylpropyl)-3,5-heptanedione or 4-(5-bromo-2,4-dimethylpentyl)-3,5-heptanedione.
By replacing the 3,5-heptanedione in the foregoing preparation by a molar equivalent amount of 2,4-pentanedione, 5,7-undecanedione or 2,2,6,6-tetramethyl-3,5-heptanedione, it is contemplated that there can be obtained, respectively, 3-(6-bromohexyl)-2,4-pentanedione, 6-(6-bromohexyl)-5,7-undecanedione, or 4-(6-bromohexyl)-2,2,6,6-tetramethyl-3,5-heptanedione.
(b) 1,3-Bis(7,7-dipropionylheptyloxy)benzene
[I; R is Ch3 CH2, Ar is 1,3-phenylene, Cm H2m ═Cn H2n ═(CH2)6 ]. Systematic nomenclature: 4,4'-[(1,3-Phenylenedioxy)bis(1,6-hexanediyl)]bis[3,5-heptanedione].
A mixture of 5.5 g. (0.05 m.) of resorcinol, 29.1 g. (0.1 m.) of 4-(6-bromohexyl)-3,5-heptanedione, 28 g. of powdered anhydrous potassium carbonate and 3 g. of potassium iodide in 200 ml. of 2-butanone was heated at reflux for 24 hours. The reaction mixture was filtered and the filtrate concentrated in vacuo. The residue was dissolved in methylene dichloride and the solution filtered and concentrated in vacuo. The residual material was distilled in vacuo (0.01 mm.) to remove material boiling up to 150° C. The remaining material was dissolved in ether, treated with activated charcoal, filtered and concentrated in vacuo. The residue was chromatographed on a column of 300 g. of silica and eluted with an equal volume mixture of ether and hexane, collecting 150 ml. fractions. The first two fractions were combined and concentrated to give 13.8 g. of 1,3-bis(7,7-dipropionylheptyloxy)benzene as a viscous yellow oil. p Anal. Calcd. for C32 H50 O6 : C, 72.42; H, 9.50. Found: C, 72.22; H, 9.56.
1,3-Bis(7,7-dipropionylheptyloxy)benzene was found to have a minimum inhibitory concentration in vitro of 12 micrograms per milliliter against Herpes virus 2.
By replacing the 4-(6-bromohexyl)-3,5-heptanedione in the foregoing preparation by a molar equivalent amount of 4-(3-bromo-2-ethylpropyl)-3,5-heptanedione, 4-(5-bromo-2,4-dimethylpentyl)-3,5-heptanedione, 3-(6-bromohexyl-2,4-pentanedione, 6-(6-bromohexyl)-5,7-undecanedione or 4-(6-bromohexyl)-2,2,6,6-tetramethyl-3,5-heptanedione, it is contemplated that there can be obtained, respectively, 1,3-bis(4,4-dipropionyl-2-ethylbutyloxy)benzene [I; R is CH3 CH2, Ar is 1,3-phenylene, Cm H2m ═Cn H2n ═CH2 CH(C2 H5)CH2 ]; 1,3-bis(6,6-dipropionyl-2,4-dimethylhexyloxy)benzene [I; R is CH3 CH2, Ar is 1,3-phenylene, Cm H2m ═Cn H2n ═CH2 CH(CH3)CH2 CH(CH3)CH2 ], 1,3-bis(7,7-diacetylheptyloxy)benzene [I; R is CH3, Ar is 1,3-phenylene, Cm H2m ═Cn H2n ═(CH2)6 ]; or 1,3-bis[7,7-bis(trimethylacetyl)heptyloxy]benzene [I; R is (CH.sub. 3)3 C, Ar is 1,3-phenylene, Cm H2m ═Cn H2n ═(CH2)6 ].
EXAMPLE 2 1,4-Bis(7,7-dipropionylheptyloxy)benzene
[I; R is CH3 CH2, Ar is 1,4-phenylene, Cm H2m ═Cn H2n ═(CH2)6 ]. Systematic nomenclature: 4,4'-[(1,4-Phenylenedioxy)bis(1,6-hexanediyl)]bis[3,5-heptanedione].
Prepared from 2.74 g. of hydroquinone and 17.5 g. of 4-(6-bromohexyl)-3,5-heptanedione according to the procedure of Example 1, part (b). The product was distilled at 235°-245° C. (0.03 mm.) and chromatographed on silica. The crystalline fractions were recrystallized from ether to give 2.2 g. of 1,4-bis(7,7-dipropionylheptyloxy)benzene, m.p. 56°-57° C.
Anal. Calcd. for C32 H50 O6 : C, 72.42; H, 9.50. Found: C, 72.19; H, 9.70.
1,4-Bis(7,7-dipropionylheptyloxy)benzene was found to have a maximum inhibitory concentration in vitro of 6 micrograms per milliliter against Herpes virus 2. It was also effective in controlling Herpes virus 2 infections in the rabbit eye.
EXAMPLE 3 1,4-Bis(8,8-dipropionyloctyloxy)benzene
[I; R is CH2 CH2, Ar is 1,4-phenylene, Cm H2m ═Cn H2n ═(CH2)7 ]. Systematic nomenclature: 4,4'-[(1,4-Phenylenedioxy)bis(1,7-heptanediyl)]bis[3,5-heptanedione].
Prepared from 3.8 g. of hydroquinone and 21 g. of 4-(7-bromoheptyl)-3,5-heptanedione (b.p. 125°-127° C., 0.03 mm.) according to the procedure of Example 1, part (b). The product was obtained in crystalline form and recrystallized from methanol to give 4.0 g. of 1,4-bis(8,8-dipropionyloctyloxy)benzene, m.p. 56°-57° C.
Anal. Calcd. for C34 H54 O6 : C, 73.09; H, 9.74. Found: C, 73.51; H, 9.86. 1,4-Bis(8,8-dipropionyloctyloxy)benzene was found to have a minimum inhibitory concentration in vitro of 25 micrograms per milliliter against Herpes virus 2.
EXAMPLE 4 1,4-Bis(7,7-dipropionylheptyloxy)-2,5-dichlorobenzene
[I; R is CH3 CH2, Ar is 2,5-dichloro-1,4-phenylene, Cm H2m ═Cn H2n ═(CH2)6 ]. Systematic nomenclature: 4,4'-[2,5-Dichloro-1,4-phenylenedioxy]-bis(1,6-hexanediyl)bis[3,5-heptanedione].
Prepared from 9.0 g. of 2,5-dichlorohydroquinone and 35.0 g. of 4-(6-bromohexyl)-3,5-heptanedione according to the procedure of Example 1, part (b). The product was distilled at 300° C. (0.005 mm.), chromatographed on 1.2 kg. of silica gel, and eluted with a mixture of 4 parts of hexane and 1 part of ethyl acetate. There was thus obtained 13.1 g of 1,4-bis(7,7-dipropionylheptyloxy)-2,5-dichlorobenzene as a yellow oil.
Anal. Calcd, for C32 H48 Cl2 O6 : C, 64.10; H, 8.07; Cl, 11.82. Found: C, 64,38; H, 8.03; Cl, 11.78.
1,4-Bis(7,7-dipropionylheptyloxy)-2,5-dichlorobenzene was found to have a minimum inhibitory concentration in vitro of 6 micrograms per milliliter against Herpes virus 2.
EXAMPLE 5 1,4-Bis(6,6-dipropionylhexyloxy)benzene
[I; R is CH3 CH2, Ar is 1,4-phenylene, Cm H2m ═Cn H2n ═(CH2)5 ]. Systematic nomenclature: 4,4'-[(1,4-Phenylenedioxy)bis(5,1-pentanediyl)]bis[3,5-heptanedione].
Prepared from 3.93 g. of hydroquinone and 19.8 g. of 4-(5-bromopentyl)-3,5-heptanedione (b.p. 115°-117° C., 0.05 mm.) according to the procedure of Example 1, part (b). The product (1.2 g.) was obtained as a colorless waxy solid.
Anal. Calcd. for C30 H46 O6 : C, 71.68; H, 9.22. Found: C, 71.63; H, 9.58.
1,4-Bis(6,6-dipropionylhexyloxy)benzene was found to have a minimum inhibitory concentration in vitro of 3 micrograms per milliliter against Herpes virus 2.
EXAMPLE 6 1,4-Bis(7,7-dipropionylheptyloxy)-2-methylbenzene
[I; R is CH3 CH2, Ar is 2-methyl-1,4-phenylene, Cm H2m ═Cn H2n ═(CH2)6 ]. Systematic nomenclature: 4,4'-[2-Methyl-1,4-phenylenedioxy]bis(1,6-hexanediyl)bis[3,5-heptanedione].
Prepared from 6.2 g. of 2-methylhydroquinone and 43.5 g. 4-(6-bromohexyl)-3,5-heptanedione according to the procedure of Example 1, part (b). The product was distilled at 250°-255° C. (0.0005 mm.) to give 11.8 g. of 1,4-bis(7,7-dipropionylheptyloxy)-2-methylbenzene as a pale yellow oil.
Anal. Calcd. for C33 H52 O6 : C, 72.76; H, 9.62. Found: C, 72.87; H, 9.74.
1,4-Bis(7,7-dipropionylheptyloxy)-2-methylbenzene was found to have a minimum inhibitory concentration in vitro of 25 micrograms per millimeter against Herpes virus 2.
EXAMPLE 7 1,4-Bis(7,7-dipropionylheptyloxy)-2-chlorobenzene
[I; R is CH3 CH2, Ar is 2-chloro-1,4-phenylene, Cm H2m ═Cn H2n ═(CH2)6 ]. Systematic nomenclature: 4,4'-[2-Chloro-1,4-phenylenedioxy]bis(1,6-hexanediyl(bis[3,5-heptanedione].
Prepared from 7.2 g. of 2-chlorohydroquinone and 43.5 g. of 4-(6-bromohexyl)-3,5-heptanedione according to the procedure of Example 1, part (b). The product was distilled at 260°-265° C. (0.01 mm.) to give 15.1 g. of 1,4-bis(7,7-dipropionylheptyloxy)-2-chlorobenzene as an orange oil.
Anal. Calcd. for C32 H49 CIO6 : C, 68.00; H, 8.74; Cl, 6.27. Found: C, 68.33; H, 9.04; Cl, 6.44.
1,4-Bis(7,7-dipropionylheptyloxy)-2-chlorobenzene was found to have a minimum inhibitory concentration in vitro of 6 micrograms per milliliter against Herpes virus 2.
By using procedures analogous to that of Example 1(b) and 7 and substituting for the 2-chlorohydroquinone of Example 7 2-fluorohydroquinone, 2-bromohydroquinone, 2-iodohydroquinone or 2-ethylhydroquinone, it is contemplated that there can be obtained, respectively, 1,4-bis(7,7-dipropionylheptyloxy)-2-fluorobenzene, 1,4-bis(7,7-dipropionylheptyloxy)-2-bromobenzene, 1,4-bis(7,7-dipropionylheptyloxy)-2-iodobenzene, or 1,4-bis(7,7-dipropionylheptyloxy)-2-ethylbenzene.
EXAMPLE 8 (a) 1,4-Bis(4-bromobutyloxy)benzene.
A solution of 14.2 g. (0.129 m.) of hydroquinone in 50 ml. of ethanol was added to a solution of 11.6 g. (0.281 m.) of sodium hydroxide in 250 ml. of ethanol, and the mixture was stirred for 15 minutes at room temperature and at 40°-45° C. for 30 minutes. The mixture was then cooled to 4° C. and 168 g. (0.780 m.) of 1,4-dibromobutane was added. The reaction mixture was stirred at room temperature for 6 hours and heated at reflux overnight. The mixture was partitioned between ether and water, the water layer washed with methylene dichloride and the combined organic layers dried over anhydrous sodium sulfate and concentrated. The residue was distilled (75°-85° C., 15 mm.) to remove excess, 1,4-dibromobutane, and the residue crystallized from methanol and recrystallized from isopropyl acetate to give 21.6 g. of 1,4-bis(4-bromobutyloxy)benzene, m.p. 89°-91° C.
(b) 1,4-Bis(5,5-dipropionylpentyloxy)benzene
[I; R is CH3 CH2 Ar is 1,4-phenylene, Cm H2m ═Cn H2n ═(CH2)4 ]. Systematic nomenclature: 4,4'-[(1,4-Phenylenedioxy)bis(4,1-butanediyl)]bis[3,5-heptanedione].
To a suspension of 1.79 g. of lithium hydride in 185 ml. of dimethylformamide was added, dropwise, 31.8 g. of 3,5-heptanedione over a 20 minute period. To the resulting lithium salt of 3,5-heptanedione was added a solution of 21.5 g. of 1,4-bis(4-bromobutyloxy)benzene in 100 ml. of dimethylformamide, and the mixture was stirred at 60°-70° C. for two days. The organic fraction of the product was isolated and unreacted 3,5-heptanedione removed by distillation (65°-68° C., 15 mm.). The remaining product crystallized and was recrystallized from an isopropyl alcohol-hexane mixture to give 6.5 g. of 1,4-bis(5,5-dipropionylpentyloxy)benzene, m.p. 51°-52° C.
Anal. Calcd. for C28 H42 O6 : C, 70.86; H, 8.92. Found: C, 70.58; H, 8.88.
1,4-Bis(5,5-dipropionylpentyloxy)benzene was found to have a minimum inhibitory concentration in vitro of 1.5 micrograms per milliliter against Herpes virus 2.
EXAMPLE 9 (a) 4-(3-Bromopropyloxy)phenol.
A mixture of 88.0 g. (0.80 m.) of hydroquinone, 161.6 g. (0.80 m.) of 1,3-dibromopropane and 55.2 g. (0.40 m.) of potassium carbonate in 2 liters of 2-butanone was heated at reflux for 24 hours. The reaction mixture was filtered and the filtrate concentrated in vacuo. The solid and liquid phases of the residue were separated, and the liquid fraction was chromatographed on silica gel using chloroform-acetonitrile (95:5) as the eluant. There was thus obtained 37.2 g. of 4-(3-bromopropyloxy)phenol as a light brown oil which was used directly in the next reaction.
(b) 1-(4-Bromobutyloxy)-4-(3-bromopropyloxy)benzene.
A mixture of 39.7 g. (0.172 m.) of 4-(3-bromopropyloxy)phenol, 148.2 g. (0.686 m.) of 1,4-dibromobutane and 10.8 g. of potassium carbonate in 1000 ml. of 2-butanone was heated at reflux for two days. The reaction mixture was filtered and concentrated in vacuo and the residue distilled to remove volatile starting materials. The residue was recrystallized from acetonitrile and then from ethanol to give 21.7 g. of 1-(4-bromobutyloxy)-4-(3-bromopropyloxy)benzene, m.p. 73°-76° C.
(c) 1-(4-Iodobutyloxy)-4-(3-iodopropyloxy)benzene.
A mixture of 31 g. (0.085 m.) of 1-(4-bromobutyloxy)-4-(3-bromopropyloxy)benzene and 25.5 g. (0.17 m.) of sodium iodide in 1000 ml. of acetone was heated at reflux for 90 minutes. The reaction mixture was filtered and the filtrate evaporated to remove the acetone. The residue was partitioned between water and methylene dichloride, and the latter dried over anhydrous magnesium sulfate and concentrated in vacuo. The residue was dried in vacuo (0.5 mm.) for 45 minutes to give 38.0 g. of 1-(4-iodobutyloxy)-4-(3-iodopropyloxy)benzene as a waxy solid used directly in the next reaction.
(d) 1-(5,5-Dipropionylpentyloxy)-4-(4,4-dipropionylbutyloxy)benzene
[I; R is CH3 CH2 ; Ar is 1,4-phenylene, Cm H2m ═(CH2)4, Cn H2n ═(CH2)3 ] was prepared from 38.0 g. of 1-(4-iodobutyloxy)-4-(3-iodopropyloxy)benzene and the lithium salt derived from 21.7 g. of 3,5-heptanedione according to the procedure of Example 8, part (b). The crude product was chromatographed on activated magnesium silicate, and eluted with the solvent series hexane-benzene-ether. An equal volume mixture of ether and benzene brought out the pure compound, 4.1 g. of 1-(5,5-dipropionylpentyloxy)-4-(4,4-dipropionylbutyloxy)benzene as a light yellow oil, structure confirmed by infrared and nuclear magnetic resonance spectra.
Anal. Calcd. for C27 H40 O6 : C, 70.40; H, 8.75. Found: C, 70.69; H, 8.63.

Claims (16)

We claim:
1. A compound of the formula ##STR3## wherein: R is alkyl of 1-4 carbon atoms;
Ar is 1,3- or 1,4-phenylene in which the phenyl ring can be further substituted by one or two methyl, ethyl or halo groups;
m and n are integers from 3 to 7, the sum of m and n ranging from 7 to 14.
2. A compound according to claim 1 wherein Ar is 1,4-phenylene and m and n are identical integers.
3. A compound according to claim 1 wherein Ar is 1,4-phenylene, m and n are identical integers and R is ethyl.
4. 1,4-Bis(7,7-dipropionylheptyloxy)benzene, according to claim 3.
5. 1,3-Bis(7,7-dipropionylheptyloxy)benzene, according to claim 1.
6. 1,4-Bis(8,8-dipropionyloctyloxy)benzene, according to claim 3.
7. 1,4-Bis(7,7-dipropionylheptyloxy)-2,5-dichlorobenzene, according to claim 1.
8. 1,4-Bis(6,6-dipropionylhexyloxy)benzene, according to claim 3.
9. 1,4-Bis(7,7-dipropionylheptyloxy)-2-methylbenzene, according to claim 1.
10. 1,4-Bis(7,7-dipropionylheptyloxy)-2-chlorobenzene, according to claim 1.
11. 1,4-Bis(5,5-dipropionylpentyloxy)benzene, according to claim 3.
12. 1-(5,5-Dipropionylpentyloxy)-4-(4,4-dipropionylbutyloxy)benzene, according to claim 1.
13. A composition for combatting viruses which comprises an antivirally effective amount of at least one compound according to claim 1 in admixture with a suitable carrier or diluent.
14. A composition according to claim 13 wherein the antivirally effective compound is 1,4-bis(5,5-dipropionylpentyloxy)benzene.
15. A method for combatting viruses which comprises contacting the locus of said viruses with a composition containing an antivirally effective amount of at least one compound according to claim 1 in admixture with a suitable carrier or diluent.
16. A method according to claim 15 wherein the anti-virally effective compound is 1,4-bis(5,5-dipropionylpentyloxy)benzene.
US05/761,944 1977-01-24 1977-01-24 Arylenedioxy-bis-diketones Expired - Lifetime US4096280A (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
US05/761,944 US4096280A (en) 1977-01-24 1977-01-24 Arylenedioxy-bis-diketones
IE8/78A IE46495B1 (en) 1977-01-24 1978-01-03 Arylenedioxy-bis-diketones
GB735/78A GB1561672A (en) 1977-01-24 1978-01-09 Arylendedioxy-bis-diketones
NZ186219A NZ186219A (en) 1977-01-24 1978-01-13 Arylenedioxy-bis-diketones and antiviral compositions
AU32468/78A AU516354B2 (en) 1977-01-24 1978-01-16 Arylenedioxy-bis-diketones
FR7801263A FR2377993A1 (en) 1977-01-24 1978-01-17 NEW ARYLENEDIOXY-BIS-DICETONES, THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS
SE7800621A SE7800621L (en) 1977-01-24 1978-01-18 PROCEDURE FOR PRODUCTION OF ORGANIC ASSOCIATIONS
CH53678A CH629741A5 (en) 1977-01-24 1978-01-18 ARYLENEDIOXY-BIS-DICETONES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS.
BE1008651A BE863007A (en) 1977-01-24 1978-01-18 NEW ARYLENEDIOXY-BIS-DICETONES, THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS
CA295,226A CA1084065A (en) 1977-01-24 1978-01-18 Phenylenedioxy-bis-diketones
DK25178A DK25178A (en) 1977-01-24 1978-01-18 PROCEDURE FOR THE PREPARATION OF ARYLENDIOXYBIS DIKETONES
LU78914A LU78914A1 (en) 1977-01-24 1978-01-19 NEW ARYLENEDIOXY-BIS-DICETONES, THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS
DE19782802281 DE2802281A1 (en) 1977-01-24 1978-01-19 NEW PHENYLENE BIS-DIKETONE, THEIR PRODUCTION AND THEIR USE
JP476078A JPS53101319A (en) 1977-01-24 1978-01-19 Arylenedioxyybissdiketone and process for preparing same
NL7800668A NL7800668A (en) 1977-01-24 1978-01-19 NEW PHENYLENE-BIS DIETONES, METHOD FOR PREPARING THEM AND PREPARATION FOR CONTROLLING VIRUSES.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US05/761,944 US4096280A (en) 1977-01-24 1977-01-24 Arylenedioxy-bis-diketones

Publications (1)

Publication Number Publication Date
US4096280A true US4096280A (en) 1978-06-20

Family

ID=25063682

Family Applications (1)

Application Number Title Priority Date Filing Date
US05/761,944 Expired - Lifetime US4096280A (en) 1977-01-24 1977-01-24 Arylenedioxy-bis-diketones

Country Status (15)

Country Link
US (1) US4096280A (en)
JP (1) JPS53101319A (en)
AU (1) AU516354B2 (en)
BE (1) BE863007A (en)
CA (1) CA1084065A (en)
CH (1) CH629741A5 (en)
DE (1) DE2802281A1 (en)
DK (1) DK25178A (en)
FR (1) FR2377993A1 (en)
GB (1) GB1561672A (en)
IE (1) IE46495B1 (en)
LU (1) LU78914A1 (en)
NL (1) NL7800668A (en)
NZ (1) NZ186219A (en)
SE (1) SE7800621L (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208425A (en) * 1977-09-06 1980-06-17 Sterling Drug Inc. Novel diketones
US4372976A (en) * 1981-08-07 1983-02-08 Sterling Drug Inc. Novel aryl-aliphatic ketone and its use as an antiviral agent

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3125059A1 (en) * 1981-06-26 1983-01-05 Bayer Ag, 5090 Leverkusen DIOXYBENZOLETHER DERIVATIVES, THESE MEDICINAL PRODUCTS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
US5185370A (en) * 1988-09-01 1993-02-09 Orion-Yhtyma Oy Substituted β-diketones and their use
IL91382A (en) * 1988-09-01 1995-06-29 Orion Yhtymae Oy Alkenyl or arylmethylene-substituted beta-diketones their preparation and pharmaceutical compositions containing them

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3541155A (en) * 1968-05-16 1970-11-17 Monsanto Co Phenoxypentanediones
US3721704A (en) * 1967-02-17 1973-03-20 Geigy Chem Corp Esters of (dialkyl-4-hydroxy-phenyl)malonic acid and related compounds
US3917718A (en) * 1972-06-22 1975-11-04 Sterling Drug Inc Cyclopropyl carbinol derivatives
US3933837A (en) * 1973-07-23 1976-01-20 Sterling Drug Inc. 3,4-Methylenedioxyphenoxy-alkyl diketones and keto-esters

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4031246A (en) * 1973-07-23 1977-06-21 Sterling Drug Inc. Aryloxyalkyl diketones

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3721704A (en) * 1967-02-17 1973-03-20 Geigy Chem Corp Esters of (dialkyl-4-hydroxy-phenyl)malonic acid and related compounds
US3541155A (en) * 1968-05-16 1970-11-17 Monsanto Co Phenoxypentanediones
US3917718A (en) * 1972-06-22 1975-11-04 Sterling Drug Inc Cyclopropyl carbinol derivatives
US3933837A (en) * 1973-07-23 1976-01-20 Sterling Drug Inc. 3,4-Methylenedioxyphenoxy-alkyl diketones and keto-esters

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208425A (en) * 1977-09-06 1980-06-17 Sterling Drug Inc. Novel diketones
US4372976A (en) * 1981-08-07 1983-02-08 Sterling Drug Inc. Novel aryl-aliphatic ketone and its use as an antiviral agent

Also Published As

Publication number Publication date
CH629741A5 (en) 1982-05-14
IE46495B1 (en) 1983-06-29
AU516354B2 (en) 1981-05-28
NL7800668A (en) 1978-07-26
NZ186219A (en) 1979-04-26
CA1084065A (en) 1980-08-19
SE7800621L (en) 1978-07-25
BE863007A (en) 1978-07-18
GB1561672A (en) 1980-02-27
JPS53101319A (en) 1978-09-04
DE2802281A1 (en) 1978-07-27
IE780008L (en) 1978-07-24
DK25178A (en) 1978-07-25
AU3246878A (en) 1979-07-26
FR2377993B1 (en) 1980-07-04
FR2377993A1 (en) 1978-08-18
LU78914A1 (en) 1978-09-28

Similar Documents

Publication Publication Date Title
Lothrop Biphenylene
CS208493B2 (en) Method of making the 6a,10a-cis-hexahydrodibenzo/b,d/-pyran-9-ons
US4031246A (en) Aryloxyalkyl diketones
US4096280A (en) Arylenedioxy-bis-diketones
US5763675A (en) Process for the preparation of 2-hydroxyarylaldehydes under reduced pressure
Skinner et al. Oxidation Products of Vitamin E and Its Model, 6-Hydroxy-2, 2, 5, 7, 8-pentamethylchroman. VIII. Oxidation with Benzoyl Peroxide1
FI85974C (en) Process for Preparation of 5- (2,5-Dimethylphenoxy) -2,2-Dimethylpentaenoic Acid
US3878200A (en) Aryl substituted tertiary carbinols
US3182061A (en) 5-[4-(p-hydroxyphenoxy)phenyl]-5-oxo-3-methylvaleric acid
US4473709A (en) Pyrethroid intermediates and process
US4208425A (en) Novel diketones
US3933837A (en) 3,4-Methylenedioxyphenoxy-alkyl diketones and keto-esters
US4153719A (en) Aromatic diketones
US4761491A (en) Preparation of 2-substituted-1,3-dioxacycloalkanes from diols and diunsaturated ethers
US4562298A (en) Optically active nordihydroguaiaretic acid and intermediates
DE2729846C2 (en) Process for the preparation of 3-position alkyl-substituted cis-1-hydroxy-6,6-dimethyl-6,6a, 7,8,10,10a-hexahydro-9H-dibenzo [b, d] pyran-9-ones
US4171371A (en) Diketones
EP0360351B1 (en) Process for the preparation of cyclopentene, cyclopentane and cyclohexane derivatives
US2479815A (en) Hydrogenation products of n-phenyl-3, 5-diethyl-2-propyldihydropyridine
US3891674A (en) Esters of aryl-aliphatic alcohols
US5468869A (en) Process for production of (azolylmethyl)-(biphenylmethyl)cyclopentanol derivatives
Fukata et al. Cyclodienones. Part 6. Preparation of 4-azido-2, 4, 6-tri-t-butyl-cyclohexa-2, 5-dienone and its thermal, photo-, and acid-catalyzed decomposition
Ismailov et al. Alkylation of Dimethyl Acetonedicarboxylate with Halogen Compounds
US2335845A (en) Ethers of polychloro-2-hydroxy-diphenyl
US3954991A (en) Mosquito larvicide

Legal Events

Date Code Title Description
AS Assignment

Owner name: SANOFI S.A., FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:STERLING WINTHROP, INC.;REEL/FRAME:008178/0289

Effective date: 19960227